Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab and Indomethacin for Exudative Age-Related Macular Degeneration
NCT03261635Phase 4Completed
- Sponsor
- University of Brescia
- Start
- Jan 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
Phase 4, randomised trial of indomethacin in age-related macular degeneration (AMD) (2 arms), sponsored by University of Brescia. Primary endpoints: Central Retinal Thickness at 12 months and Visual Acuity at 12 months. Started Jan 2016; status: completed.
02
Drugs
indomethacin
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT03261635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261635.